Please use this identifier to cite or link to this item:
http://ir.mu.ac.ke:8080/jspui/handle/123456789/7088
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Weelderen, Romy E. van | - |
dc.contributor.author | Njuguna, Festus | - |
dc.contributor.author | Klein, Kim | - |
dc.contributor.author | Mostert, Saskia | - |
dc.contributor.author | Langat, Sandra | - |
dc.contributor.author | Vik, Terry A. | - |
dc.contributor.author | Olbara, Gilbert | - |
dc.contributor.author | Kipng'etich, Martha | - |
dc.contributor.author | . Kaspers, Gertjan J. L | - |
dc.date.accessioned | 2022-11-16T08:40:16Z | - |
dc.date.available | 2022-11-16T08:40:16Z | - |
dc.date.issued | 2021-06-14 | - |
dc.identifier.uri | http://ir.mu.ac.ke:8080/jspui/handle/123456789/7088 | - |
dc.description.abstract | Background: Pediatric acute myeloid leukemia (AML) is a challenging disease to treat in low- and middle-income countries (LMICs). Literature suggests that survival in LMICs is poorer compared with survival in high-income countries (HICs). Aims: This study evaluates the outcomes of Kenyan children with AML and the impact of sociodemographic and clinical characteristics on outcome. Methods and Results: A retrospective medical records study was performed at Moi Teaching and Referral Hospital (MTRH) in Eldoret, Kenya, between January 2010 and December 2018. Sociodemographic and clinical characteristics, and treatment outcomes were evaluated. Chemotherapy included two “3 + 7” induction courses with doxorubicin and cytarabine and two “3 + 5” consolidation courses with etoposide and cytarabine. Supportive care included antimicrobial prophylaxis with cotrimoxazole and fluconazole, and blood products, if available. Seventy-three children with AML were included. The median duration of symptoms before admission at MTRH was 1 month. The median time from admission at MTRH to diagnosis was 6 days and to the start of AML treatment 16 days. Out of the 55 children who were started on chemotherapy, 18 (33%) achieved complete remission, of whom 10 (56%) relapsed. The abandonment rate was 22% and the early death rate was 46%. The 2-year probabilities of event-free survival and overall survival were 4% and 7%, respectively. None of the sociodemographic and clinical characteristics were significantly associated with outcome. Conclusion: Survival of Kenyan children with AML is dismal and considerably lower compared with survival in HICs. Strategies to improve survival should be put in place including better supportive care, optimization of the treatment protocol, and reduction of the abandonment rate and time lag to diagnosis with sooner start of treatment | en_US |
dc.description.sponsorship | Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands 2Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands 3Child Health and Pediatrics, Moi University/ Moi Teaching and Referral Hospital, Eldoret, Kenya 4Wilhelmina Children's Hospital/University Medical Center Utrecht, Utrecht, The Netherlands 5Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA | en_US |
dc.publisher | Wiley | en_US |
dc.subject | Kenya | en_US |
dc.subject | Low- and middle-income countries | en_US |
dc.subject | Pediatric acute myeloid leukemia | en_US |
dc.subject | Sub-Saharan Africa | en_US |
dc.subject | Survival | en_US |
dc.title | Outcomes of pediatric acute myeloid leukemia treatment in Western Kenya | en_US |
dc.type | Article | en_US |
Appears in Collections: | School of Medicine |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.